Findings

What do systematic reviews say?

259 questions · 296 findings · 91 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 111 · 37.5%GRADE not reported 130 · 43.9%Very low 30 · 10.1%Low 8 · 2.7%Moderate 12 · 4.1%High 5 · 1.7%

Oral antibiotics vs IV antibiotics

Quality of life · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral methotrexate vs oral chloroquine

Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FLUPHENAZINE (ORAL) vs QUETIAPINE

Quality of life (long term) · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings for resveratrol plus oral anti‐diabetic drugs vs placebo plus oral anti‐diabetic drugs

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Resveratrol for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral magnesium pidolate vs placebo or no intervention

Quality of life · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral factor Xa inhibitors vs conventional anticoagulation

Health‐related quality of life · patients with a pulmonary embolism, confirmed by standard imaging techniques

The review found no eligible studies for this question.

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral steroids vs placebo

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

1 finding from 1 review

Topical and oral steroids for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

FLUPHENAZINE (ORAL) vs RISPERIDONE

Quality of life (long term) ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs OLANZAPINE

Quality of life (long term) ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs AMISULPRIDE

Quality of life (long term) ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Very low

Summary of findings: oral β‐carotene vs placebo

Quality of life · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral creatine vs placebo

Change in quality of life · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Oral direct thrombin inhibitors (DTIs) vs conventional anticoagulation

Health‐related quality of life · patients with a pulmonary embolism, confirmed by standard imaging techniques

The review found no eligible studies for this question.

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral olesoxime vs placebo

Change in quality of life · non‐ambulatory children and adolescents with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 108 participants
Low

Summary of findings: oral vitamin E supplementation vs placebo or no treatment

Quality of life · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral gabapentin vs placebo

Change in quality of life · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Low

Oral appliance or functional orthopaedic appliance vs placebo or no treatment

Quality of life (validated questionnaire) · Children with obstructive sleep apnoea (aged 15 years or younger)

The review found no eligible studies for this question.

1 finding from 1 review

Oral appliances and functional orthopaedic appliances for obstructive sleep apnoea in children 2016 · Cochrane All outcomes
The included study did not assess this outcome.
0 studies
No studies found